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The use of a quantitative structure-activity relationship (QSAR) model to 
predict GABA-A receptor binding of newly emerging benzodiazepines 
 
 
 
 
 There is a deficiency in the pharmacological data available for new benzodiazepines.  
 69 benzodiazepines were used to develop a quantitative structure-activity relationship 
(QSAR).  
 The resultant QSAR model returned an R2 value of 0.90. 
 This model will allow rapid prediction of the pharmacology of emerging 
benzodiazepines. 
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Abstract 4 
The illicit market for new psychoactive substances is forever expanding. Benzodiazepines 5 
and their derivatives are one of a number of groups of these substances and thus far their 6 
number has grown year upon year. For both forensic and clinical purposes it is important to 7 
be able to rapidly understand these emerging substances. However as a consequence of the 8 
illicit nature of these compounds, there is a deficiency in the pharmacological data available 9 
for these ‘new’ benzodiazepines. In order to further understand the pharmacology of ‘new’ 10 
benzodiazepines we utilised a quantitative structure-activity relationship (QSAR) approach. 11 
A set of 69 benzodiazepine-based compounds was analysed to develop a QSAR training set 12 
with respect to published binding values to GABAA
 
receptors. The QSAR model returned an 13 
R
2
 value of 0.90. The most influential factors were found to be the positioning of two H-bond 14 
acceptors, two aromatic rings and a hydrophobic group. A test set of nine random compounds 15 
was then selected for internal validation to determine the predictive ability of the model and 16 
gave an R
2
 value of 0.86 when comparing the binding values with their experimental data. 17 
The QSAR model was then used to predict the binding for 22 benzodiazepines that are 18 
classed as new psychoactive substances. This model will allow rapid prediction of the 19 
binding activity of emerging benzodiazepines in a rapid and economic way, compared with 20 
lengthy and expensive in vitro/in vivo analysis. This will enable forensic chemists and 21 
toxicologists to better understand both recently developed compounds and prediction of 22 
substances likely to emerge in the future.  23 
 24 
Keywords: benzodiazepines; QSAR; biological activity; prediction; new psychoactive 25 
substances; GABAA receptor 26 
manuscript
2 
 
Introduction 27 
Benzodiazepines and their derivatives are routinely prescribed for a variety of medical 28 
conditions as anxiolytic, anti-insomnia and anti-convulsant drugs, acting on the gamma-29 
aminobutyric acid type A (GABAA) receptor [1, 2]. The endogenous neurotransmitter for the 30 
GABAA receptor is gamma-aminobutyric acid (GABA), the binding of which reduces the 31 
excitability of the cell [3]. Benzodiazepines potentiate the response of the GABAA receptor to 32 
GABA which results in far less cellular excitability which,  in physiological terms, results in 33 
sedation and relaxation [1]. 34 
In these circumstances benzodiazepines are medically beneficial by alleviating stress and 35 
agitation in patients through their anxiolytic effects. However, as a result of their 36 
psychoactive effects, benzodiazepines have a long history of abuse and are often illicitly 37 
obtained [4-6].  In more recent years a steady stream of benzodiazepines have appeared on 38 
the illicit market that have either been newly-synthesised or are licensed as prescription drugs 39 
in another country but not in the home country [7-10]. These are termed ‘new psychoactive 40 
substances’ (NPS) [11, 12]. The majority of these emerging benzodiazepines have not 41 
undergone standard pharmaceutical trials and can be quite variant in their effects and 42 
potentially dangerous in their activity [13]. Although relatively safe when used as medically 43 
prescribed, concurrent use of benzodiazepines and opioids (either prescribed or abused) can 44 
lead to respiratory depression and death [4, 14, 15]. When benzodiazepines are not carefully 45 
prescribed and monitored, they can cause a variety of side effects including tolerance and 46 
dependency if taken long-term and sudden withdrawal can cause medical problems including 47 
anxiety and insomnia [16-18]. These NPS benzodiazepines have already been reported in a 48 
number of overdose cases, driving under the influence of drugs (DUID) cases and hospital 49 
admissions [8, 19-22]. The lack of control and safety over these illicit benzodiazepines is a 50 
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prevalent issue and it is likely that it will become an even more worrying trend as their 51 
misuse continues to rise.  52 
Benzodiazepines are a diverse group of psychoactive compounds with a central structural 53 
component consisting of a benzene ring and a diazepine ring (Figure 1). A whole host of 54 
derivatives exist which include triazolobenzodiazepines, thienotriazolobenzodiazepines and 55 
imidazobenzodiazepines (see Supplementary Information Figure S1 and Table S1).  56 
Quantitative structure-activity relationship (QSAR) models attempt to correlate molecular 57 
structure to biological activity, often using a variety of molecular descriptors such as 58 
physiochemical, topological, electronic and steric properties [23]. Typically, a set of 59 
compounds whose biological activity is known is used to create a ‘training’ dataset and a 60 
model. This model can then be used to predict the unknown biological activity of compounds 61 
with a similar structure or to explore the structural features that are important for the specific 62 
biological activity in question. QSAR has been extensively used for a variety of reasons such 63 
as compound development in the pharmaceutical industry and the pharmacological 64 
interpretation of drug-related deaths [24-26]. In terms of applications towards new 65 
psychoactive substances, the predictive power of QSAR has been mainly applied to 66 
cannabinoid binding to the CB1 and CB2 receptors [27-29] but has also been used to examine 67 
the biological activity of hallucinogenic phenylalkylamines [30], the binding of 68 
phenylalkylamines, tryptamines and LSD to the 5-HT2A receptor [31] and methcathinone 69 
selectivity for dopamine (DAT), norepinephrine (NAT) and serotonin transporters (SERT) 70 
[32].  Currently, the majority of novel benzodiazepines have not been analysed to determine 71 
their physicochemical and biological properties as this would require a substantial investment 72 
in both time and money. It is for this reason that a fast, yet economical method to predict their 73 
properties is desirable. 74 
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QSAR has previously been applied to benzodiazepines to predict bioavailability, absorption 75 
rate, clearance, half-life and volume of distribution for a group of benzodiazepines. This 76 
study included phenazepam [33], a benzodiazepine that appeared as an NPS in 2007 [34].  77 
Other benzodiazepines (such as etaziolam) only appeared as new psychoactive substances in 78 
the years following the publication of this study. Furthermore, the application of a QSAR 79 
methodology has been used for modelling post-mortem redistribution of benzodiazepines 80 
where a good model was obtained (R
2
 = 0.98) in which energy, ionisation and molecular size 81 
were found to exert significant impact [35]. Quantitative structure-toxicity relationships  82 
(QSTR) have been used to correlate the toxicity of benzodiazepines to their structure in an 83 
attempt to predict the toxicity of these compounds  [36]. More recently, a study reported the 84 
use of QSTR whereby it was concluded that it is possible to identify structural fragments 85 
responsible for toxicity (the presence of amine and hydrazone substitutions as well as 86 
saturated heterocyclic ring systems resulted in a greater toxicity) and potentially use this 87 
information to create new, less toxic benzodiazepines for medical use [37].  88 
Various QSAR models have been used to correlate benzodiazepine structure to GABAA 89 
receptor binding and tease apart the complex relationship between various substituents and 90 
their effect on activity [38-43] although none have specifically attempted to predict binding 91 
values for benzodiazepines that are new psychoactive substances. 92 
In this study we focus on the relationship between the structure of characterised 93 
benzodiazepines and GABAA receptor binding, expressed as the logarithm of the reciprocal 94 
of concentration (log 1/c) where c is the molar inhibitory concentration (IC50) required to 95 
displace 50 % of [3H]-diazepam from rat cerebral cortex synaptosomal preparations [41]. 96 
The purpose of this work is to create a QSAR model that can be used to predict the potential 97 
biological activity of the newly-emerging benzodiazepines to help understand, and therefore 98 
minimise their harmful potential in a faster time scale compared with in vitro/in vivo testing.  99 
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Methods and Materials 100 
Selection of the dataset 101 
The binding data for the benzodiazepines was used as obtained from the literature, 102 
experimentally determined using spectrometric measurements of [3H]-diazepam 103 
displacement [44]. Benzodiazepines were selected from four categories; 1,4-benzodiazepines, 104 
triazolobenzodiazepines, imidazobenzodiazepines and thienotriazolobenzodiazepines.  105 
Benzodiazepines that did not have definitive binding values (i.e. listed values were simply 106 
stated as >1000 or >5000) were excluded. For simplicity benzodiazepines with atypical atoms 107 
or substituents (e.g. Ro 07-9238 which contained a sodium atom and Ro 05-5065 which 108 
contained a naphthalene ring) were also excluded. Benzodiazepines that also had atypical 109 
substitutions (i.e. positions R6, R8 and R9 from Figure 1 which are not found in medically-110 
used benzodiazepines or indeed those that are new psychoactive substances) were also 111 
excluded. In total, 88 benzodiazepines were selected for the training dataset. 112 
QSAR/Software and Data Analysis Method 113 
The 88 benzodiazepines were converted from SMILES to 3D structures based on Merck 114 
Molecular Force Field (MMFF) atom type and force field optimisation. These compounds 115 
were then aligned by common substructure and confirmation to Ro 05-306. Subsequently, the 116 
aligned compounds were clustered by Atomic Property Fields (APF) to identify 117 
benzodiazepines with poor alignment. The APF method, designed by MolSoft, uses the 118 
assignment of a 3D pharmacophore potential on a continuously distributed grid using physio-119 
chemical properties of the selected compound(s) to classify or superimpose compounds. 120 
These properties include: hydrogen bond donors, acceptors, Sp2 hybridisation, lipophilicity, 121 
size, electropositivity/negativity and charge [45, 46]. Poorly aligned benzodiazepines 122 
identified by APF clustering were subjected to re-alignment using APF-based flexible 123 
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superimposition. At this point, 10 benzodiazepines with poor alignment were removed to 124 
improve model accuracy. (Supplementary Information Table 1S). 125 
From the remaining 78 aligned compounds, 9 compounds were selected using a random 126 
number generator based on atmospheric noise. These compounds were removed from the 127 
training set and used for final model validation. The residual 69 compounds were used as the 128 
training set to build a 3D QSAR model, as shown in Figure 2.  129 
The APF 3D QSAR method was used where, for each of the 69 aligned compounds, the 130 
seven physicochemical properties were calculated and pooled together. Based on the activity 131 
data obtained from literature and the 3D aligned structures for the known compounds, 132 
weighted contributions for each APF component were obtained to allow quantitative activity 133 
predictions for unknown compounds. The optimal weight distributions were assigned by 134 
partial least-squares (PLS) methodology, where the optimal number of latent vectors for PLS 135 
was established by leave-one-out cross-validation on the training set. Then the weighted 136 
contributions were added together. The 9 compounds for validation and unknown compounds 137 
were assigned predicted binding values by calculating their fit within the combined QSAR 138 
APF. Any unknown benzodiazepines were subjected to the conversion and alignment 139 
protocol before predicted binding data was obtained. The above steps were conducted using 140 
Molsoft’s ICM Pro software [47]. 141 
Further analysis of the PLS model fragment contributions from the 69 compounds was 142 
conducted using SPCI software. Here, a 2D QSAR model was built using the same PLS 143 
methodology as above. Additionally, a consensus model was created from averaging the 144 
predictions of PLS, gradient boosting, support vector machine and random forest modelling 145 
methods. The compounds were then subjected to automatic fragmentation and contribution 146 
calculations, which resulted in information on 11 key contributing groups [48]. Using Ligand 147 
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Scout with default settings, four ligand-based pharmacophore models were created using 148 
compounds with binding values of 6.0-9.0, 7.0-9.0, 8.0-9.0 and 8.5-9.0, as exemplified in 149 
Figure 3. 150 
Ten benzodiazepines that had the highest predicted binding values were docked into a 151 
modelled GABAA5 receptor using ICM software. The GABAA5 receptor model was generated 152 
by homology modelling, using the crystal structure of a human GABA(A)R-beta3 153 
homopentamer (PDB id 4COF) as a template. A pre-defined binding site containing co-154 
crystallised benzodiazepine is already present in the template, which was retained in the final 155 
model. Modeller software was used to generate the homology models [49]. The final chosen 156 
model was energy minimized using the ACEMD software [50]. The stereochemistry was 157 
checked using Procheck and ProSA software [51, 52]. The benzodiazepine in the allosteric 158 
binding site on the GABAA5 receptor was used as a chemical template to dock NPS-159 
benzodiazepines and the best-scoring conformations were analysed.  160 
The distances between principle physiochemical properties and their weights in the 161 
pharmacophore model were calculated using the software LigandScout [53]. 162 
163 
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Results and Discussion 164 
The data that was used to create the QSAR model (i.e. benzodiazepine structural substitutions 165 
and experimentally-observed binding values) is provided in the Supplementary Information 166 
(Table S1). 167 
From the pharmacophore model visualised in Figure 3 for highly bound benzodiazepines (log 168 
1/c of 8.0 – 9.0), it is evident that important binding features for the benzodiazepines were the 169 
positioning of two H-bond acceptors, two aromatic rings and a hydrophobic group all with 170 
weights of 1.0. 171 
The predicted binding values are not presented here but are listed in Supplementary 172 
Information (Table S1). They can be visualised in Figure 4 as a plot of the observed binding 173 
value versus the predicted binding value.   174 
Nine compounds were selected at random from the QSAR training set and their binding 175 
values estimated using the model as a system of internal validation. These estimated values 176 
were then compared to the experimental binding values (Figure 5).  177 
The QSAR model was then used to predict the binding for 22 benzodiazepines that are 178 
classed as new psychoactive substances. The results are divided in to four categories 179 
depending upon the nature of the substitutions, as shown in Tables 1, 2, 3 and 4.  180 
Five compounds were present in the training dataset but have also appeared as new 181 
psychoactive substances; adinazolam, desalkylflurazepam, desmethylflunitrazepam 182 
(fonazepam), etizolam and meclonazepam. The experimental binding values from the 183 
literature and the predicted binding values are displayed in Table 5.  184 
The NPS-benzodiazepine with the highest predicted log 1/c value was flunitrazolam with 185 
8.88, closely followed by clonazolam with 8.86. However, based upon experimental data, 186 
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meclonazepam with a log 1/c value of 8.92 (8.52 predicted) actually exhibited the greatest 187 
binding affinity. Only two benzodiazepines in the training set experimental values had a log 188 
1/c value of 8.92; these were meclonazepam and brotizolam with the rest falling below this 189 
point. In general, the limitations to this model are most likely caused by the small size of the 190 
data set. It is widely reported that QSAR models have poorer predictive capabilities with 191 
training sets under 100 compounds [54, 55]. Moreover, the diversity of substitutions within 192 
the small set of training compounds, created difficulties with APF superimposition and 193 
therefore may have reduced the accuracy of the model predictors. Secondary modelling with 194 
SPCI highlighted these limitations and demonstrated the existing dataset was less suitable for 195 
PLS 2D QSAR modelling [48]. However, the consensus from multiple modelling methods 196 
improves the predictive power of the 2D QSAR model.  Additionally, as experimental errors 197 
in the training set are amplified both by the logarithmic scale and when calculating the 198 
weighted contributions, consistency and accuracy in the initial experimental values are 199 
essential for a strong QSAR model. Ideally, further improvements to the model could be 200 
made by using a larger training dataset with lower diversity yet this cannot be achievable as a 201 
consequence of limitations on literature data available. 202 
From these docking studies with the modelled GABAA5 receptor it can be seen that they only 203 
partially occupy the available volume at the allosteric binding site (exemplified in Figure 6 204 
for flunitrazolam). From the ten compounds that had the greatest binding affinity, four had 205 
non-bonded interactions with the T80 region within the receptor, two had non-bonded 206 
interactions with the K182 and S231 regions respectively. There were also stacking 207 
interactions with the Y96 region for four of the compounds. Therefore the possibility is that 208 
the binding is not completely optimal for these benzodiazepines and that with a modified 209 
chemical structure, a greater binding affinity could be theoretically possible. The reality 210 
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exists that a benzodiazepine with an optimised binding affinity could emerge onto the illicit 211 
drugs market and could potentially (but not necessarily) exhibit a greater potency. 212 
The 10 compounds with the greatest binding affinity for the receptor are listed in Table 6 213 
(lower scores indicate a greater binding effect).  214 
There are 35 benzodiazepines and their derivatives currently subject to international control, 215 
30 of these compounds had binding values listed in the original source [44]. The average log 216 
1/c value for these 30 controlled compounds was 7.57. Out of these compounds, 43 % (13 out 217 
of 30) had a log 1/c value that was greater than 8.00. The average log 1/c value for the whole 218 
training dataset was 7.81 and 48 % of the compounds (33 out of 69) had a log 1/c value that 219 
was greater than 8.00. These values are fairly similar, however when comparing the results of 220 
the benzodiazepines that are new psychoactive substances, the average log 1/c value that was 221 
predicted was 8.22 and 68 % of the compounds (15 out of 22) had a log 1/c value that was 222 
greater than 8.00. From this it is appears that benzodiazepines that are appearing as new 223 
psychoactive substances are more likely to have a greater binding affinity at the GABAA 224 
receptor. Whether this trend is deliberate is unclear.  225 
A log 1/c value of 7.88 was obtained for 4-chlorodiazepam (Ro 5-4864). This suggests a 226 
relatively high affinity for the GABAA receptor when compared with the log 1/c values for 227 
clinically-used benzodiazepines; the binding value for diazepam is 8.09 and 8.40 for 228 
triazolam. However it has been reported that the experimental value for 4-chlorodiazepam 229 
(Ro-4864) is actually 3.79 (i.e. an IC50 value of 160,500 nM) in one dataset when compared 230 
with a log 1/c of 7.80 for diazepam and 8.72 for triazolam in the same dataset [56]. There are 231 
obvious impracticalities with comparing different datasets as a result of differences in 232 
methods (e.g. the use of [
3
H]-diazepam versus [
3
H]-flunitrazepam as a radioligand), the 233 
differences in the species used (rat vs. mouse) and the differences in GABAA receptor 234 
expression between different brain homogenates. Despite this it is clear that 4-235 
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chlorodiazepam observes an extremely low affinity for GABAA receptors and one that this 236 
model did not accurately predict. This most likely results from the deficit of compounds in 237 
the training dataset that had a similar substitution on the R4’ position of the phenyl ring. 238 
Indeed, this model focused upon the ‘classical’ 1,4-benzodiazepine, triazolobenzodiazepine, 239 
imidazobenzodiazepine and thienotriazolodiazepine substitutions. Substitutions on the R4’ 240 
position of the phenyl ring are known to exhibit strong steric repulsion at the GABAA 241 
receptor interface and therefore compound binding is severely inhibited [40] [57]. 4-242 
chlorodiazepam is an outlier and atypical benzodiazepine as it does not act upon the GABAA 243 
receptor; instead exerting its pharmacological effects through the translocator protein 18 kDa 244 
(TSPO), previously known as the peripheral benzodiazepine receptor [58, 59]. 245 
 246 
The oxazolobenzodiazepine flutazolam, a prescription drug in Japan, had a predicted log 1/c 247 
binding value of 6.83 which seems extremely low compared with the other benzodiazepines 248 
in this dataset. To the best of the authors’ knowledge there exists no experimental GABAA 249 
receptor binding data for flutazolam. However other oxazolobenzodiazepines have low 250 
affinities for the GABAA receptor such as ketazolam with a log 1/c value of 5.89 [60] and 251 
oxazolam with a log 1/c value of 5.00 [61]. These log 1/c binding values are from additional 252 
sources – the previous paragraph discusses the difficulties in comparing binding values from 253 
different datasets. Nonetheless it is clear that oxazolobenzodiazepines exhibit a much lower 254 
affinity for the GABAA receptor.   If the value for flutazolam is correct then this QSAR 255 
model successfully predicted the low binding affinity of flutazolam despite having no 256 
oxazolobenzodiazepines in the training dataset which serves as an indicator to the potential 257 
strength of the model. 258 
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Conclusions 259 
The emergence of benzodiazepines and their derivatives as new psychoactive substances 260 
necessitates the investigation of their pharmacological attributes. The use of a QSAR model 261 
is ideal to gain an understanding into the binding properties of these substances. In this work 262 
a QSAR model has been successfully developed to predict the binding data for NPS-263 
benzodiazepines. Benzodiazepines that have emerged as new psychoactive substances appear 264 
to have a greater binding affinity to GABAA receptors than those benzodiazepines that are 265 
used medically and are under international control. Whether this trend will continue is 266 
uncertain. Further in vitro work would allow the compilation of more data to improve the 267 
accuracy of this model. However, this model does allow a rapid estimation of the binding 268 
affinity of emerging benzodiazepines before more detailed studies can be carried out. 269 
270  
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 493 
Tables 494 
 495 
Table 1. Structural information and predicted binding values for 1,4-benzodiazepines 496 
Name 
Substitutions Log 1/c 
predicted 
Basic structure 
R7 R1 R2' R3 
Diclazepam Cl CH3 Cl - 8.39 
 
Desalkylflurazepam Cl - F - 8.44 
Meclonazepam NO2 - Cl CH3 8.52 
Phenazepam Br - Cl - 8.12 
Desmethylflunitrazepam NO2 - F - 8.46 
3-hydroxyphenazepam Br - Cl OH 8.42 
Flubromazepam F - Br - 8.37 
Nifoxipam NO2 - F OH 8.63 
Cloniprazepam NO2 - Cl C3H5CH3 7.83 
Nimetazepam NO2 CH3 - - 7.87 
4-chlorodiazepam
a
 Cl CH3 - - 7.88 
a4-chlorodiazepam has a Cl substituted on the R4’ position of the phenyl ring 
 
 
 
 
 497 
 498 
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Table 2. Structural information and predicted binding values for triazolobenzodiazepines 499 
 500 
 501 
Table 3. Structural information and predicted binding values for thienotriazolodiazepines 502 
Name 
Substitutions Log 1/c 
predicted 
Basic structure 
R9 R2 R2' 
Deschloroetizolam CH3 CH2CH3 - 7.96 
 
Etizolam CH3 CH2CH3 Cl 8.64 
Metizolam - CH2CH3 Cl 8.34 
 503 
Name 
Substitutions Log 1/c 
predicted 
Basic structure 
R8 R1 R2' R4 
Flubromazolam Br CH3 F - 8.77 
 
Clonazolam NO2 CH3 Cl - 8.86 
Flunitrazolam NO2 CH3 F - 8.88 
Bromazolam NO2 CH3 - - 8.25 
Adinazolam Cl CH3N(CH3)2 - - 7.18 
Pyrazolam
a
 Br CH3 - - 7.79 
Nitrazolam NO2 CH3 - - 8.34 
aPyrazolam has a 2-pyridyl ring at position 6 rather than a phenyl ring 
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Table 4. Structural information and a predicted binding value for an oxazolobenzodiazepine 504 
 505 
 506 
Table 5. Observed and predicted binding values for new psychoactive substances 507 
Compound 
Log 1/c 
observed 
Log 1/c 
predicted 
% (log 1/c obs.) / (log 1/c pred.) 
Adinazolam 6.87 7.18 95.9 % 
Desalkylflurazepam 8.70 8.44 103.1 % 
Desmethylflunitrazepam 
(fonazepam) 
8.82 8.46 104.3 % 
Etizolam 8.51 8.64 98.5 % 
Meclonazepam 8.92 8.52 104.7 % 
 508 
 509 
 510 
 511 
 512 
 513 
 514 
Name 
Substitutions Log 1/c 
predicted 
Basic Structure 
R10 R7 R2' 
Flutazolam Cl CH2CH2OH F 6.83 
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Table 6. Binding scores and molecular descriptors of the 10 compounds exhibiting the 515 
greatest binding affinity for the receptor 516 
 517 
Compound 
Name 
Score  Numb
er of 
Atoms 
in 
ligand 
Number 
of 
rotatable 
torsions 
Hydrogen 
Bond 
energy 
hydroph
obic 
energy 
in 
exposin
g a 
surface 
to water  
van der 
Waals 
interacti
on 
energy  
internal 
conformation 
energy of the 
ligand  
desolvation 
of exposed 
h-bond 
donors and 
acceptors 
solvation 
electrostatics 
energy change 
upon binding  
potential 
of mean 
force score 
Flunitrazola
m 
-17.9003 37 1 -1.55071 -6.12229 -
27.3992 
4.10324 10.7377 13.4407 -158.403 
Clonazolam -15.4617 37 1 -1.53992 -6.124 -
27.9233 
7.64508 11.6698 16.8309 -154.162 
Flubromazol
am 
-18.2738 35 0 -1.61755 -6.89366 -
25.8773 
3.57746 11.0855 12.122 -151.357 
Etizolam -18.7025 38 1 -2.03733 -7.14073 -
25.5154 
7.89581 11.8052 11.0572 -101.516 
Nifoxipam -20.836 33 2 -5.90608 -4.9646 -22.352 6.0639 12.5432 13.905 -129.57 
Meclonazepa
m 
-13.4447 35 1 -2.27939 -5.98463 -
21.8787 
5.69717 10.6159 14.6192 -124.257 
Desmethylflu
nitrazepam 
-15.5192 32 2 -0.82246 -5.27009 -
26.2114 
2.37454 10.376 11.0938 -144.474 
Desalkylflura
zepam 
-21.7837 30 0 -2.01574 -5.82939 -27.462 0.691701 9.53716 11.4106 -154.372 
Diclazepam -16.8002 33 0 -0.60989 -6.76567 -25.688 2.00693 10.3028 10.9647 -121.093 
Metizolam -13.7614 35 1 -1.78622 -6.65559 -
24.7768 
3.51234 14.5321 12.8708 -138.056 
 518 
 519 
 520 
 521 
 522 
 523 
 524 
 525 
 526 
 527 
 528 
 529 
 530 
 531 
 532 
 533 
 534 
 535 
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Figures 536 
 537 
 538 
Figure 1: The basic structural formula for benzodiazepines considered in this work 539 
 540 
 541 
Figure 2: Alignment of 69 training set benzodiazepines shown in two orientations. 542 
24 
 
 543 
Figure 3: Pharmacophore model of 33 compounds with binding values 8.0-9.0  544 
 545 
 546 
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 547 
Figure 4: Literature (i.e. observed) binding values (log 1/c) vs. QSAR predicted binding 548 
values fit with a partial least squares (PLS) regression (R
2
 = 0.90).  549 
 550 
26 
 
 551 
Figure 5: Literature (i.e. observed) binding values (log 1/c) vs. QSAR predicted binding 552 
values for 9 compounds randomly selected for internal validation (R
2
 = 0.86).  553 
 554 
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 555 
 556 
Figure 6: Visualisation of the NPS-benzodiazepine flunitrazolam binding to the allosteric 557 
site of the GABAA5 receptor 558 
 559 
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